EUVIMEDEUVIMED entdecken
Validierungsstudie

Methylation-based test for diagnosis of benign and malignant melanocytoma

Wen-Wen Zhang, Long-Feng Ke, Yu Chen, Chen-Yu Wu, Shu-Yi Lu, Yun-Li Xie, Huan-Huan Zhu, Hao Chen, Gang Chen, Yan-Ping Chen iD

British Journal of Dermatology · 2025

DOI: 10.1093/bjd/ljaf169 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift British Journal of Dermatology, 2025. Verfasst von Wen-Wen Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China. Hauptthemen laut MEDLINE: DNA Methylation, Melanoma, Skin Neoplasms, Nevus, Pigmented. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Natural Science Foundation of Fujian Province, Innovation of Science and Technology, Fujian province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The accurate diagnosis of melanoma significantly improves patient survival rates. Distinguishing melanomas from naevi purely by morphology can be challenging when neoplastic cells are confined to the epidermis or lack marked nuclear pleomorphism.

Objectives

To investigate candidate DNA methylation alterations that can distinguish melanoma from naevus; to develop an efficient and convenient methylation-specific quantitative real-time polymerase chain reaction assay (MS-qPCR) for the diagnosis of melanoma; and to validate the diagnostic performance of the MS-qPCR.

Methods

We collected 145 formalin-fixed paraffin embedded tissue (FFPE) samples of malignant melanoma, 143 FFPE samples of benign naevus, 31 plasma samples from patients with melanoma and 37 plasma samples from healthy control skin between March 2018 and July 2024. The FFPE samples were divided into a discovery set, a training set and a validation set. PRAME, CLDN11 and SHOX2 promoter methylation levels were detected in the discovery set by pyrosequencing, to identify melanoma-specific methylation markers. Using these genes, we developed an efficient and convenient MS-qPCR diagnostic model and validated its diagnostic performance in the training set, validation set and plasma samples.

Results

Pyrosequencing in the discovery set showed that PRAME and CLDN11 promoter methylation levels were significant diagnostic biomarkers of melanoma; no significant differences in SHOX2 promoter methylation were found between melanoma and naevi. MS-qPCR for the detection of PRAME and CLDN11 methylation levels was established. A diagnostic algorithm based on cycle threshold values was constructed and achieved high accuracy in the training set (sensitivity 94.3%, specificity 85.6%), validation set (sensitivity 84.5%, specificity 88.7%) and plasma samples (sensitivity 51.6%, specificity 83.8%). In terms of melanoma subtypes, the diagnostic algorithm enabled a high degree of discrimination between acral (sensitivity 89.9%, specificity 86.4%) and mucosal melanoma (sensitivity 100%, specificity 83.3%). More importantly, the diagnostic algorithm was able to distinguish early-stage melanoma from normal naevus, with an area under the curve of 0.879 and sensitivity of 77.3%.

Conclusions

The approach to detecting PRAME and CLDN11 methylation levels using MS-qPCR has high sensitivity and specificity in the differential diagnosis between benign and malignant melanocytic tumours. Using this approach in plasma is a promising and easily implementable strategy for early melanoma screening.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA MethylationMelanomaSkin NeoplasmsNevus, PigmentedHumansFemaleMaleDiagnosis, DifferentialBiomarkers, TumorMiddle AgedReal-Time Polymerase Chain ReactionPromoter Regions, GeneticAdultAntigens, NeoplasmAgedSensitivity and SpecificityCase-Control Studies

Substanzen

Biomarkers, TumorPRAME protein, humanAntigens, Neoplasm

Autor:innen und Institutionen

  • Department of Pathology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
  • Department of Molecular Pathology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
  • Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
  • Department of Pathology, Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China.

ORCID-Profile: Yan-Ping Chen

Förderung

  • Natural Science Foundation of Fujian Province
  • Innovation of Science and Technology
  • Fujian province
  • Fujian Medical University
  • Health Science and Technology Plan of Fujian Province
  • Medical Innovation Program of Fujian Provincial Healthcare Commission
  • Innovation Fund for Medical Sciences and Clinical Translational Project

Zitieren

APA

Zhang, W. W., Ke, L. F., Chen, Y., Wu, C. Y., Lu, S. Y., Xie, Y. L., Zhu, H. H., Chen, H., Chen, G., & Chen, Y. P. (2025). Methylation-based test for diagnosis of benign and malignant melanocytoma. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljaf169

Vancouver

Zhang WW, Ke LF, Chen Y, Wu CY, Lu SY, Xie YL, et al. Methylation-based test for diagnosis of benign and malignant melanocytoma. British Journal of Dermatology. 2025. doi:10.1093/bjd/ljaf169

BibTeX
@article{Zhang2025,
  author = {Zhang, Wen-Wen and Ke, Long-Feng and Chen, Yu and Wu, Chen-Yu and Lu, Shu-Yi and Xie, Yun-Li and Zhu, Huan-Huan and Chen, Hao and Chen, Gang and Chen, Yan-Ping},
  title = {Methylation-based test for diagnosis of benign and malignant melanocytoma},
  journal = {British Journal of Dermatology},
  year = {2025},
  doi = {10.1093/bjd/ljaf169}
}
Kostenlos starten →